Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H16ClN3O2 |
| Molecular Weight | 365.813 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NOC2=C1C3=C(C=CC=C3)C(=N[C@H]2CC(N)=O)C4=CC=C(Cl)C=C4
InChI
InChIKey=GCWIQUVXWZWCLE-INIZCTEOSA-N
InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1
| Molecular Formula | C20H16ClN3O2 |
| Molecular Weight | 365.813 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:31:52 UTC 2023
by
admin
on
Sat Dec 16 10:31:52 UTC 2023
|
| Record UNII |
U4017GUQ06
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CPI-0610
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
57389999
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
11382
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
DTXSID201022544
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
CPI-0610 ANHYDROUS
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | MedKoo CAT NO.: 206117, CAS NO.: 1380087-89-7Description: CPI-0610 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor CPI-0610 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. (Last updated: 5/18/2016). | ||
|
300000007881
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
C111901
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
U4017GUQ06
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY | |||
|
1380087-89-7
Created by
admin on Sat Dec 16 10:31:52 UTC 2023 , Edited by admin on Sat Dec 16 10:31:52 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
SOLVATE->ANHYDROUS | |||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-.KAPPA.B. Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clinical trials for hematological malignancies (CPI-0610).
|
